Pilot study of extracorporeal removal of soluble Fms-like tyrosine kinase 1 in preeclampsia

Circulation

Volumn 124, Issue 8, 2011, Pages 940-950

  Thadhani, Ravi ^a   Kisner, Tuelay ^b   Hagmann, Henning ^b   Bossung, Verena ^c   Noack, Stefanie ^c   Schaarschmidt, Wiebke ^f   Jank, Alexander ^f   Kribs, Angela ^c   Cornely, Oliver A ^d,e   Kreyssig, Claudia ^g   Hemphill, Linda ^a   Rigby, Alan C ^c   Khedkar, Santosh ^c   Lindner, Tom H ^g   Mallmann, Peter ^c   Stepan, Holger ^f   Karumanchi, S Ananth ^c,h,i   Benzing, Thomas ^b,c,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Center for Molecular Medicine   (Germany)

^c Department of Obstetrics and Gynecology ^*

^d Clinical Trials Center   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f Division of Nephrology   (Germany)

^g UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

angiogenic factor; apheresis; preeclampsia

Indexed keywords

DEXTRAN SULFATE; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ADULT; APHERESIS; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; FEMALE; FETUS OUTCOME; GESTATIONAL AGE; HUMAN; PILOT STUDY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEINURIA;

ADULT; BLOOD COMPONENT REMOVAL; CELLULOSE; DEXTRAN SULFATE; FEMALE; HUMANS; PILOT PROJECTS; PRE-ECLAMPSIA; PREGNANCY; PROTEIN STRUCTURE, TERTIARY; SOLUBILITY; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 80052149662     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.034793     Document Type: Article

References (55)

1. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308:1592-1594. (Pubitemid 40807500)
2. Alexander GR, Kogan M, Bader D, Carlo W, Allen M, Mor J. US birth weight/gestational age-specific neonatal mortality: 1995-1997 rates for whites, hispanics, and blacks. Pediatrics. 2003;111:e61-e66.
3. Mathews TJ, MacDorman MF. Infant mortality statistics from the 2004 period linked birth/infant death data set. Natl Vital Stat Rep. 2007; 55:1-32.
4. Thadhani R. Inching towards a targeted therapy for preeclampsia. Hypertension. 2010;55:238-240.
5. Odendaal HJ, Pattinson RC, Bam R, Grove D, Kotze TJ. Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks' gestation: a randomized controlled trial. Obstet Gynecol. 1990;76:1070-1075.
6. Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol. 1994;171: 818-822. (Pubitemid 24312370)
7. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989;161:1200-1204. (Pubitemid 20007682)
8. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004;95:884-891. (Pubitemid 39435003)
9. Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee Kim Y, Goncalves LF, Gomez R, Edwin S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol. 2004;190:1541-1550. (Pubitemid 39006187)
10. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683. (Pubitemid 38364626)
11. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-658. (Pubitemid 36278583)
12. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E, Goncalves L, Gomez R, Edwin S, Mazor M. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med. 2005;17:3-18. (Pubitemid 40515938)
13. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2010;202:161e1-161e11.
14. Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and angiogenic imbalance. Annu Rev Med. 2008;59:61-78. (Pubitemid 351287924)
15. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, Fischer P, Ronnen E, Ishill N, Patil S, Motzer RJ. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1432-1439.
16. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs B, Sibai B, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992-1005. (Pubitemid 44343543)
17. Davison JM. Dialysis, transplantation, and pregnancy. Am J Kidney Dis. 1991;17:127-132.
18. Martin JN Jr, Perry KG Jr, Roberts WE, Norman PF, Files JC, Blake PG, Morrison JC, Wiser WL. Plasma exchange for preeclampsia: II. Unsuccessful antepartum utilization for severe preeclampsia with or without HELLP syndrome. J Clin Apher. 1994;9:155-161.
19. Wu FT, Stefanini MO, Mac Gabhann F, Popel AS. A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS One. Published online April 8,2009. doi: 10.1371/journal.pone. 0005108. 2009, 4, e5108.
20. Park M, Lee ST. The fourth immunoglobulin-like loop in the extracellular domain of FLT-1, a VEGF receptor, includes a major heparin-binding site. Biochem Biophys Res Commun. 1999;264:730-734.
21. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99:11393-11398. (Pubitemid 34920936)
22. Vuorela P, Helske S, Hornig C, Alitalo K, Weich H, Halmesmaki E. Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet Gynecol. 2000;95:353-357. (Pubitemid 30100498)
23. Bambauer R, Schiel R, Latza R. Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies. Ther Apher. 2000;4:213-217. (Pubitemid 30445875)
24. Bosch T, Schmidt B, Kleophas W, Gillen C, Otto V, Passlick-Deetjen J, Gurland HJ. LDL hemoperfusion-a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with human whole blood. Artif Organs. 1997;21:977-982. (Pubitemid 27380934)
25. Klingel R, Fassbender T, Fassbender C, Gohlen B. From membrane differential filtration to lipidfiltration: technological progress in lowdensity lipoprotein apheresis. Ther Apher Dial. 2003;7:350-358. (Pubitemid 36859526)
26. Teruel JL, Lasuncion MA, Navarro JF, Carrero P, Ortuno J. Pregnancy in a patient with homozygous familial hypercholesterolemia undergoing lowdensity lipoprotein apheresis by dextran sulfate adsorption. Metabolism. 1995;44:929-933.
27. Soffronoff EC, Kaufmann BM, Connaughton JF. Intravascular volume determinations and fetal outcome in hypertensive diseases of pregnancy. Am J Obstet Gynecol. 1977;127:4-9. (Pubitemid 8018569)
28. Sela S, Natanson-Yaron S, Zcharia E, Vlodavsky I, Yagel S, Keshet E. Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase. Circ Res. 2011;108:1063-1070.
29. Bosch T, Heinemann O, Duhr C, Wendler T, Keller C, Fink E, Kirschner T, Klebert S, Samtleben W. Effect of low-dose citrate anticoagulation on the clinical safety and efficacy of direct adsorption of lipoproteins (DALI apheresis) in hypercholesterolemic patients: a prospective controlled clinical trial. Artif Organs. 2000;24:790-796.
30. Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int. 1999;55:1991-1997. (Pubitemid 29197989)
31. Davis-Smyth T, Presta LG, Ferrara N. Mapping the charged residues in the second immunoglobulin-like domain of the vascular endothelial growth factor/placenta growth factor receptor Flt-1 required for binding and structural stability. J Biol Chem. 1998;273:3216-3222. (Pubitemid 28109731)
32. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 1993;90:10705-10709. (Pubitemid 23347111)
33. Zwiener RJ, Uauy R, Petruska ML, Huet BA. Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia. J Pediatr. 1995;126:728-735.
34. Klingel R, Gohlen B, Schwarting A, Himmelsbach F, Straube R. Differential indication of lipoprotein apheresis during pregnancy. Ther Apher Dial. 2003;7:359-364. (Pubitemid 36859527)
35. Kroon AA, Swinkels DW, van Dongen PW, Stalenhoef AF. Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis. Metabolism. 1994;43: 1164-1170. (Pubitemid 24286581)
36. Heydarian M, McCaffrey T, Florea L, Yang Z, Ross MM, Zhou W, Maynard SE. Novel splice variants of sFlt1 are upregulated in preeclampsia. Placenta. 2009;30:250-255.
37. Kaplan AA. A simple and accurate method for prescribing plasma exchange. ASAIO Trans. 1990;36:M597-M599. (Pubitemid 20367142)
38. ACOG Practice Bulletin. Assessment of risk factors for preterm birth. Clinical management guidelines for obstetrician-gynecologists. Number 31, October 2001. (Replaces Technical Bulletin number 206, June 1995; Committee Opinion number 172, May 1996; Committee Opinion number 187, September 1997; Committee Opinion number 198, February 1998; and Committee Opinion number 251, January 2001). Obstet Gynecol. 2001;98:709-716.
39. Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I, Lam A, O'Young G, Sannajust F, Stathis P, Schreiner G, Karumanchi SA, Protter AA, Pollitt NS. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension. 2007;50:686-692. (Pubitemid 47442732)
40. Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, Schaaps JP, Cabrol D, Frankenne F, Foidart JM. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab. 2003;88:5555-5563. (Pubitemid 37452769)
41. von Dadelszen P, Ornstein M, Bull S, Logan A, Koren G, Magee L. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. The Lancet. 2000;355:87-92. (Pubitemid 30068551)
42. Haig D. Genetic conflicts in human pregnancy. Q Rev Biol. 1993;68: 495-532. (Pubitemid 2031412)
43. Hirashima M, Lu Y, Byers L, Rossant J. Trophoblast expression of fms-like tyrosine kinase 1 is not required for the establishment of the maternal-fetal interface in the mouse placenta. Proc Natl Acad Sci USA. 2003;100:15637-15642. (Pubitemid 38021042)
44. Hladunewich MA, Steinberg G, Karumanchi SA, Levine RJ, Keating S, Kingdom J, Keunen J. Angiogenic factor abnormalities and fetal demise in a twin pregnancy. Nat Rev Nephrol. 2009;5:658-662.
45. Stepan H, Faber R. Elevated sFlt1 level and preeclampsia with parvovirus-induced hydrops. N Engl J Med. 2006;354:1857-1858.
46. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129-1136. (Pubitemid 351398487)
47. Smithies O. Why the kidney glomerulus does not clog: a gel permeation/diffusion hypothesis of renal function. Proc Natl Acad Sci USA. 2003; 100:4108-4113. (Pubitemid 36418165)
48. Sibai BM, Barton JR. Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. Am J Obstet Gynecol. 2007;196:514 e511-e519.
49. Morcel K, Lavoue V, Beuchee A, Le Lannou D, Poulain P, Pladys P. Perinatal morbidity and mortality in twin pregnancies with dichorionic placentas following assisted reproductive techniques or ovarian induction alone: a comparative study. Eur J Obstet Gynecol Reprod Biol. 2010; 153:138-142.
50. Dechend R, Homuth V, Wallukat G, Kreuzer J, Park JK, Theuer J, Juepner A, Gulba DC, Mackman N, Haller H, Luft FC. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation. 2000;101:2382-2387. (Pubitemid 30329128)
51. Blaha M, Cermanova M, Blaha V, Jarolim P, Andrys C, Blazek M, Maly J, Smolej L, Zajic J, Masin V, Zimova R, Rehacek V. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. Atherosclerosis. 2008;197: 264-270. (Pubitemid 351273248)
52. Stoffel W, Demant T. Selective removal of apolipoprotein B-containing serum lipoproteins from blood plasma. Proc Natl Acad Sci USA. 1981; 78:611-615. (Pubitemid 11140738)
53. Wang Y, Walli AK, Schulze A, Blessing F, Fraunberger P, Thaler C, Seidel D, Hasbargen U. Heparin-mediated extracorporeal low density lipoprotein precipitation as a possible therapeutic approach in preeclampsia. Transfus Apher Sci. 2006;35:103-110. (Pubitemid 44793143)
54. Fisk NM, Atun R. Market failure and the poverty of new drugs in maternal health. PLoS Med. 2008;5:e22.
55. Boguski MS, Mandl KD, Sukhatme VP. Drug discovery Repurposing with a difference. Science. 2009;324:1394-1395.